Interaction between Ezetimibe and Cholestyramine
Moderate
Others
| ID | DDInter707 and DDInter368 |
| Interaction | INTERVAL: In a study of 40 healthy hypercholesterolemic adults, concomitant administration of cholestyramine (4 g twice daily) decreased the mean area under the plasma concentration-time curve (AUC) of total ezetimibe by approximately 55%. The incremental LDL cholesterol reduction expected with the addition of ezetimibe to cholestyramine or other bile acid sequestrants may be diminished by this interaction. |
| Management | Ezetimibe should be administered at least 2 hours before or 4 hours after the bile acid sequestrant. |
| References | |
| Alternative for Ezetimibe |
C10B
C10A
More
|
| Alternative for Cholestyramine |
C10A
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.